Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 13Terminated 2Active not recruiting 2Unknown 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 35Lymphoma, Large B-Cell, Diffuse 22Sarcoma 19Lymphoma 19Carcinoma, Hepatocellular 12Precursor Cell Lymphoblastic Leukemia-Lymphoma 11Lymphoma, Non-Hodgkin 9Hodgkin Disease 9Multiple Myeloma 8Leukemia 8Neuroblastoma 6Liver Neoplasms 6Lymphoma, Follicular 5Immunoblastic Lymphadenopathy 5Ovarian Neoplasms 4Lymphoma, T-Cell, Peripheral 4Lymphoma, Mantle-Cell 4Triple Negative Breast Neoplasms 3Recurrence 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Osteosarcoma 3Neoplasms, Plasma Cell 3Lymphoma, Large-Cell, Immunoblastic 3Lymphoma, Large-Cell, Anaplastic 3Liposarcoma 3Leiomyosarcoma 3Chondrosarcoma 3Burkitt Lymphoma 3Wilms Tumor 2Rhabdomyosarcoma 2

Interventions

Fluorouracil 3Cyclophosphamide 3pegfilgrastim 2Paclitaxel 2Immunoenzyme Techniques 2Epirubicin 2Chemotherapy, Adjuvant 2Biopsy 2Bevacizumab 2Amplified Fragment Length Polymorphism Analysis 2orantinib 1eribulin 1Zoledronic Acid 1Therapeutics 1Taxes 1Sorafenib 1Radiotherapy 1Radioimmunodetection 1Pyridoxine 1Psychiatric Rehabilitation 1Neoadjuvant Therapy 1Methotrexate 1Magnetic Resonance Spectroscopy 1Immunologic Techniques 1Ibandronic Acid 1Gene Rearrangement 1Gene Expression Profiling 1Flow Cytometry 1Drug Screening Assays, Antitumor 1Doxorubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Breast Neoplasms, Male × Doxorubicin × Clear all
NCT00436709 2014-01-06

Bevacizumab, Doxorubicin, and Cyclophosphamide Followed By Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients Who Have Undergone Surgery for Early-Stage Breast Cancer

National Cancer Institute (NCI)

Phase NA Unknown
75 enrolled
Breast

Breast Neoplasms, Breast Neoplasms, Male

Data powered by HemOnc (CC BY 4.0) Colophon âš¡